The clinical stage biotechnology company said it extended its collaboration with Vertex through Q1 2020 with options to extend further based on future progress. The research collaboration and licensing agreement, first signed in July 2016, was aimed at the discovery and development of mRNA therapeutics for the treatment of cystic fibrosis.
The company also reported Q2 net loss of $135.1 million, down from last year's loss of $90.6 million and narrower than the consensus loss estimate of $148.4 from analysts polled by Capital IQ.
Moderna posted Q2 revenue of $13.1 million, declining from $28.9 million a year and fell short of the $18.4 million Capital IQ consensus revenue estimate.
Price: 13.23, Change: +0.94, Percent Change: +7.65
|2021 Earnings Projection for ProAssurance Bumped Up|
|QTS Realty Trust Sees Analysts Target Lower Forecast...|
|Pebblebrook Hotel Trust Sees Analysts Scale Down Out...|
|Analysts Trim Douglas Dynamics' Q1, 2020, and 2021 E...|
|Parsley Energy's Q1 and 2020 Estimates Trimmed but 2...|